Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
Zhang Y, Zhou H, Jiang Z, Wu D, Zhuang J, Li W, Jiang Q, Wang X, Huang J, Zhu H, Yang L, Du X, Li F, Xia R, Zhang F, Hu J, Li Y, Hu Y, Liu J, Jin C, Sun K, Zhou Z, Wu L, Yin H, Suo S, Yu W, Jin J.
Zhang Y, et al. Among authors: sun k.
Am J Hematol. 2024 Apr;99(4):774-779. doi: 10.1002/ajh.27245. Epub 2024 Feb 11.
Am J Hematol. 2024.
PMID: 38343062
Clinical Trial.